Evaluation of Aegle marmelos (Bael) as Hyperglycemic and Hyperlipidemic Diminuting agent in type ii diabetes mellitus Subjects
Kriti Sharma, Swati Shukla, Ekta Singh Chauhan
Background: Diabetes mellitus is possibly the world’s largest growing metabolic disease. The International Diabetes Federation (IDF) estimates the total number of people in India with diabetes to be around 50.8 million in 2010, rising to 87.0 million by 2030. With such incidence, mere nutrition and medical therapies cannot be relied upon. Currently, a challenge is to identify such healthy foods that remain in the realms of obscurity and to establish them as functional foods to prevent the progression of metabolic complications. Aegle Marmelos is one of the most widely used medicinal and nutraceutical plant. Leaves, fruits, stem and roots of Aegle Marmelos have been used in ethno medicine to exploit its various medicinal properties including antioxidant, antimicrobial, antidiahrreal, antidiabetic, antiproliferative, hepatoprotective, anti-inflammatory, antihyperlipidemic antiasthamtic and antiulcer activities. Therefore, this study was undertaken to evaluate the effect of Aegle Marmelos fruit pulp powder on type II diabetic subjects. Methods: Type II diabetic subjects were selected from main campus of Banasthali University, Newai Rajasthan and divided into experimental and control groups (Age group: 30-60 years). Aegle Marmelos fruit pulp powder was incorporated in khakre and administered to the experimental group daily for 60 days. Biochemical evaluations of blood sample of the subjects were done. Results: The present study indicates that Aegle Marmelos fruit pulp powder showed a significant effect on blood glucose and lipid parameters. Conclusion: Aegle Marmelos purport to alleviate the symptoms of diabetes in a natural manner having no side effects on health and inexpensive than other hypoglycemic drugs.
How to cite this article:
Kriti Sharma, Swati Shukla, Ekta Singh Chauhan. Evaluation of Aegle marmelos (Bael) as Hyperglycemic and Hyperlipidemic Diminuting agent in type ii diabetes mellitus Subjects. Pharma Innovation 2016;5(5):43-46.